PE20211267A1 - Metodos de tratamiento de la insuficiencia cardiaca con fraccion de eyeccion reducida con dapagliflozina - Google Patents

Metodos de tratamiento de la insuficiencia cardiaca con fraccion de eyeccion reducida con dapagliflozina

Info

Publication number
PE20211267A1
PE20211267A1 PE2020000563A PE2020000563A PE20211267A1 PE 20211267 A1 PE20211267 A1 PE 20211267A1 PE 2020000563 A PE2020000563 A PE 2020000563A PE 2020000563 A PE2020000563 A PE 2020000563A PE 20211267 A1 PE20211267 A1 PE 20211267A1
Authority
PE
Peru
Prior art keywords
heart failure
dapagliflozin
methods
ejection fraction
treatment
Prior art date
Application number
PE2020000563A
Other languages
English (en)
Inventor
Anna Maria Langkilde
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of PE20211267A1 publication Critical patent/PE20211267A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Fodder In General (AREA)

Abstract

La presente divulgacion se refiere a metodos de tratamiento de pacientes con insuficiencia cardiaca con fraccion de eyeccion reducida (HFrEF), con y sin diabetes de tipo 2, con un inhibidor de SGLT2 tal como dapagliflozina. Los metodos desvelados en el presente documento reducen el riesgo de un resultado combinado de un primer episodio de empeoramiento de insuficiencia cardiaca (hospitalizacion por insuficiencia cardiaca o una visita de urgencias por insuficiencia cardiaca) o muerte por causas cardiovasculares. Tambien puede reducirse cada uno de los tres componentes de este resultado combinado, asi como el numero total de hospitalizaciones por insuficiencia cardiaca y muertes por causas cardiovasculares. Los inhibidores de SGLT2, tales como dapagliflozina, tambien pueden reducir un empeoramiento de los sintomas de insuficiencia cardiaca. Los metodos desvelados en el presente documento tambien pueden mejorar los sintomas de insuficiencia cardiaca, el estado de salud y la calidad de vida.
PE2020000563A 2019-08-30 2020-03-09 Metodos de tratamiento de la insuficiencia cardiaca con fraccion de eyeccion reducida con dapagliflozina PE20211267A1 (es)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962893849P 2019-08-30 2019-08-30
US201962930673P 2019-11-05 2019-11-05
US201962946625P 2019-12-11 2019-12-11
US202062960756P 2020-01-14 2020-01-14
US202062969181P 2020-02-03 2020-02-03
US202062985407P 2020-03-05 2020-03-05
PCT/EP2020/056211 WO2021037400A1 (en) 2019-08-30 2020-03-09 Methods of treating heart failure with reduced ejection fraction with dapagliflozin

Publications (1)

Publication Number Publication Date
PE20211267A1 true PE20211267A1 (es) 2021-07-19

Family

ID=69784449

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2020000563A PE20211267A1 (es) 2019-08-30 2020-03-09 Metodos de tratamiento de la insuficiencia cardiaca con fraccion de eyeccion reducida con dapagliflozina

Country Status (18)

Country Link
US (3) US10973836B2 (es)
EP (1) EP4021507A1 (es)
JP (2) JP2022530575A (es)
KR (2) KR102359799B1 (es)
CN (1) CN112752582A (es)
AU (3) AU2020202887B2 (es)
BR (1) BR112020008705A2 (es)
CA (1) CA3079175A1 (es)
CL (1) CL2020001335A1 (es)
CR (1) CR20200224A (es)
IL (1) IL274020A (es)
JO (1) JOP20200098A1 (es)
MX (2) MX2020005388A (es)
PE (1) PE20211267A1 (es)
PH (1) PH12020551141A1 (es)
SG (1) SG11202003971RA (es)
TW (2) TWI786398B (es)
WO (1) WO2021037400A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021000601A (es) 2018-07-19 2021-04-13 Astrazeneca Ab Metodos de tratamiento de hfpef empleando dapagliflozina y composiciones que comprenden la misma.
SG11202003971RA (en) 2019-08-30 2021-04-29 Astrazeneca Ab Methods of treating heart failure with reduced ejection fraction with dapagliflozin
WO2022144465A1 (en) * 2021-01-04 2022-07-07 Charité-Universitätsmedizin Berlin Sotagliflozin for improving left atrial function
WO2023144722A1 (en) 2022-01-26 2023-08-03 Astrazeneca Ab Dapagliflozin for use in the treatment of prediabetes or reducing the risk of developing type 2 diabetes
JP7396579B2 (ja) 2022-01-31 2023-12-12 壽製薬株式会社 左室駆出率が保たれた心不全に対する医薬組成物
WO2023175573A1 (en) * 2022-03-17 2023-09-21 Zydus Lifesciences Limited Pharmaceutical compositions comprising a β-blocker and an sglt2 inhibitor
WO2023192848A1 (en) * 2022-03-28 2023-10-05 University Of Maryland, Baltimore Methods and compositions for the treatment of stroke
WO2024047574A1 (en) * 2022-09-01 2024-03-07 Astrazeneca Ab Combination of sglt2 inhibitors and mineralcorticoid receptor modulators for use in treatment of cardiorenal diseases
KR20240099022A (ko) * 2022-12-20 2024-06-28 주식회사 티에치팜 나트륨 포도당 운반체-2 저해제 및 안지오텐신 ⅱ 수용체 차단제를 함유하는 경구용 약학 제제

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12000002657B1 (en) 1999-10-12 2006-02-21 Bristol Myers Squibb Co C-aryl glucoside SGLT2 inhibitors
US6515117B2 (en) 1999-10-12 2003-02-04 Bristol-Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
KR20080102395A (ko) 2006-02-15 2008-11-25 베링거 인겔하임 인터내셔날 게엠베하 글루코피라노실-치환된 벤조니트릴 유도체, 당해 화합물을 함유하는 약제학적 조성물, 이들의 용도 및 이들의 제조방법
TW200904454A (en) * 2007-03-22 2009-02-01 Bristol Myers Squibb Co Methods for treating obesity employing an SGLT2 inhibitor and compositions thereof
PE20090185A1 (es) * 2007-03-22 2009-02-28 Bristol Myers Squibb Co Formulaciones farmaceuticas que contienen un inhibidor sglt2
CA2812016A1 (en) 2013-04-05 2014-10-05 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
WO2016001631A1 (en) * 2014-06-30 2016-01-07 Astrazeneca Ab Benzoxazinone amides as mineralocorticoid receptor modulators
RU2695652C2 (ru) * 2014-09-25 2019-07-25 Астразенека Аб Комбинация омега-3 жирной кислоты и SGLT-2 ингибитора для лечения болезней печени
KR20180122004A (ko) 2016-03-16 2018-11-09 베링거 인겔하임 인터내셔날 게엠베하 엠파글리플로진을 포함하는 약제학적 조성물 및 이의 용도
JPWO2018043463A1 (ja) * 2016-08-30 2019-06-24 国立大学法人 新潟大学 老化細胞除去薬
WO2018142422A1 (en) 2017-02-02 2018-08-09 Indoco Remedies Limited Process for the preparation of dapagliflozin
KR101943382B1 (ko) 2017-09-19 2019-01-29 오토텔릭바이오 주식회사 Sglt-2 저해제 및 안지오텐신 수용체 차단제를 포함하는 의약 조성물
MX2021000601A (es) 2018-07-19 2021-04-13 Astrazeneca Ab Metodos de tratamiento de hfpef empleando dapagliflozina y composiciones que comprenden la misma.
SG11202003971RA (en) 2019-08-30 2021-04-29 Astrazeneca Ab Methods of treating heart failure with reduced ejection fraction with dapagliflozin
US20220023252A1 (en) * 2020-07-27 2022-01-27 Astrazeneca Ab Methods of treating chronic kidney disease with dapagliflozin

Also Published As

Publication number Publication date
JP2022530575A (ja) 2022-06-30
US20210260083A1 (en) 2021-08-26
TW202108134A (zh) 2021-03-01
WO2021037400A1 (en) 2021-03-04
US11903955B2 (en) 2024-02-20
PH12020551141A1 (en) 2021-05-31
SG11202003971RA (en) 2021-04-29
AU2020202887A1 (en) 2021-03-18
US10973836B2 (en) 2021-04-13
CN112752582A (zh) 2021-05-04
KR20210027229A (ko) 2021-03-10
AU2021215150B2 (en) 2023-05-04
JP2023025207A (ja) 2023-02-21
JP7494277B2 (ja) 2024-06-03
CL2020001335A1 (es) 2021-07-09
EP4021507A1 (en) 2022-07-06
BR112020008705A2 (pt) 2022-03-22
AU2021215150A1 (en) 2021-09-02
IL274020A (en) 2021-03-01
JOP20200098A1 (ar) 2021-02-28
MX2022008018A (es) 2022-07-27
MX2020005388A (es) 2022-10-25
CA3079175A1 (en) 2021-02-28
CR20200224A (es) 2021-05-26
TWI786398B (zh) 2022-12-11
US20240216404A1 (en) 2024-07-04
US20210060043A1 (en) 2021-03-04
KR102359799B1 (ko) 2022-02-09
KR20220044234A (ko) 2022-04-07
AU2020202887B2 (en) 2021-05-20
TW202335668A (zh) 2023-09-16
AU2023210548A1 (en) 2023-08-17

Similar Documents

Publication Publication Date Title
PE20211267A1 (es) Metodos de tratamiento de la insuficiencia cardiaca con fraccion de eyeccion reducida con dapagliflozina
DOP2021000273A (es) Agonistas del receptor del péptido-1 similar al glucagón
CL2020002401A1 (es) Composiciones de arni de 17 b-hidroxiesteroide deshidrogenasas tipo 13 (hsd17b13) y métodos de uso de las mismas.
CL2020001742A1 (es) Inhibidores de glicolato oxidasa para el tratamiento de enfermedades
MX2020004005A (es) Terapias genicas para los trastornos lisosomales.
MX2020003965A (es) Terapias genicas para los trastornos lisosomales.
DOP2017000097A (es) Composiciones y métodos de uso para tratar trastornos metabólicos
CO2018009561A2 (es) Métodos para tratar la depresión con antagonistas del receptor de orexina-2
CL2021003374A1 (es) Inhibidores de glicolato oxidasa para el tratamiento de enfermedades
CL2023001351A1 (es) Métodos de tratamiento de la insuficiencia cardíaca mediante la administración de omecamtiv mecarbil.
CO6410306A2 (es) Inhibidor de sglt2 para tratar diabetes mellitus de tipo 1, diabetes mellitus de tipo 2, alteración de la tolerancia a la glucosa e hiperglucemia
BR112022004699A2 (pt) Vs-6063 em combinação com ch5126766 para o tratamento de câncer
WO2015117010A3 (en) Bag3 as a target for therapy of heart failure
EA201101187A1 (ru) Антидиабетические лекарственные средства, содержащие ингибитор dpp-4 (линаглиптин) необязательно в комбинации с другими антидиабетическими средствами
Na et al. Cervical ganglion block attenuates the progression of pulmonary hypertension via nitric oxide and arginase pathways
ECSP19001018A (es) Moduladores del receptor adrenérgico beta -3 útiles para el tratamiento o prevención de trastornos relacionados con los mismos
CO2021015505A2 (es) Tratamiento de la disfunción sistólica e insuficiencia cardíaca con fracción de eyección reducida con el compuesto (r) -4-(1-((3-(difluorometil) -1-metil-1h-pirazol-4-il) sulfonil) -1-fluoroetil) -n-(isoxazol-3-il) piperidin-1-carboxamida
CL2011001943A1 (es) Terapia antibiotica para tartar o prevenir el sindrome del intestino irritable post- infeccioso.
BR112021020183A2 (pt) Terapias gênicas para distúrbios lisossomais
BR112022007721A2 (pt) Método para o tratamento da demência
AR118963A1 (es) Métodos de tratamiento de la insuficiencia cardíaca con fracción de eyección reducida con dapagliflozina
MX2020003243A (es) Métodos para tratar la insuficiencia cardíaca con fracción de eyección preservada.
MX2022004910A (es) Metodos de tratamiento de los sintomas del trastorno del espectro autista.
AR082278A1 (es) Vacunas de enterovirus para prevenir o tratar diabetes tipo 1 (iii)
CO2022006772A2 (es) Composiciones y métodos para el tratamiento de los trastornos de almacenamiento de glucógeno